Author Archive: BIOtechNOW Editor

Prosensa’s IPO and the Value of the BIO Investor Forum

Hans Schikan

Prosensa (NASDAQ: RNA) is a Dutch biotechnology company engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders. Our primary focus is on rare neuromuscular and neurodegenerative disorders with a large unmet medical need, including Duchenne muscular dystrophy, myotonic dystrophy and Huntington’s disease. We completed an IPO onto NASDAQ in June of this year. Prior to last year’s BIO Investor Forum in San Francisco, we were still in the very Read More >

The One-on-One Compass  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

McKew_115x76

On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders to join us for our inaugural “Research & Development Day” September 12 in Cambridge, Mass. Novartis Institutes for Biomedical Research will host the event at which researchers will showcase therapeutic candidates for indications such as sickle cell disease, hereditary inclusion body myopathy, Duchenne muscular dystrophy and cryptococcal meningitis to potential partners. To register and view the agenda, visit https://events-support.com/events/NCATS_RandD_Day. The Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Driving Innovation in Breast Cancer: Startup Challenge

Driving Innovation

The Avon Foundation (AF), National Institutes of Health National Cancer Institute (NCI) and Center for Advancing Innovation (CAI) have partnered to launch a “first of a kind” Business Plan and Start-Up Challenge for Breast Cancer (BC) inventions that have high commercial viability and are important to public health. This challenge will accelerate the commercialization of Federal agency and AF grantee BC inventions, spur economic growth, and provide Universities a platform to further develop their entrepreneurship learning portfolio. Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , ,

Involving Patients in the Research Process

PsAM-2013-Facebook-Shareable115x76

According to the National Psoriasis Foundation, as many as 7.5 million Americans live with psoriasis, making it the most common autoimmune disease in the country. More than just a skin condition, psoriasis puts people at increased risk for other serious diseases such as heart disease, diabetes and depression. Up to 30 percent of people with psoriasis develop psoriatic arthritis, an inflammatory joint disease. A complex disease with a genetic component, psoriasis is not contagious. While Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Propel Small Business Innovation through Tax Reform

Jeffery_Hatfield copy

As CEO of an emerging clinical-stage biotech company, I lose over $10 million each year. Over the lifetime of my company, I have lost over $100 million. But constantly losing money in an effort to advance discoveries should not overshadow the real lifeblood of biotechnology, which is the reward of seeing patients treated, lives saved, and families healed. Some of the biggest challenges companies like mine face include high research and production costs, coupled with Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,